Gene · 8081
AD5: Alzheimer disease 5
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. AD5: Alzheimer disease 5. Genes, record 8081. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8081
On this page
Gene
- Symbol
- AD5
- Name
- Alzheimer disease 5
- NCBI Gene ID
- 8081
- Type
- unknown
Source NCBI Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,163
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AD5 papers | Newest fiscal year |
|---|---|---|---|
| UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 31 | 2025 |
| UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 27 | 2025 |
| UM1AI068635 | SDMC: HIV Vaccine Trials Network | 23 | 2025 |
| ZIAAI005035 | HIV Vaccine Studies | 12 | 2025 |
| R37AI054165 | Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | 10 | 2025 |
| P30AI050409 | Center for AIDS Research at Emory University | 8 | 2025 |
| P30AI027757 | University of Washington/Fred Hutch Center for AIDS Research | 7 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 7 | 2025 |
| UM1AI069481 | Seattle Clinical Trials Unit | 7 | 2025 |
| ZIAAI005073 | Immune correlates of protection | 7 | 2025 |
1 to 10 of 1,163Source NIH's project files
See all 1,163 nih grantsPapers1,614
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A mechanistic model for recombinant adeno-associated virus production dynamics in a helper virus-assisted producer cell line. | Biotechnol Prog | 2026 | 42244226 | PubTator, text mining | PubMed |
| An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. | Proc Natl Acad Sci U S A | 2026 | 42054358 | PubTator, text mining | PubMed |
| Progress in the research and development of oncolytic virus therapies. | Front Pharmacol | 2026 | 41800095 | PubTator, text mining | PubMed |
| Development and psychometric validation of caring leadership scale in nursing. | PLoS One | 2026 | 41770765 | PubTator, text mining | PubMed |
| Differential assembly of RNP granules via activation of distinct dsRNA sensors by adenovirus mutants. | bioRxiv | 2026 | 41756847 | PubTator, text mining | PubMed |
| Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas. | Front Neurol | 2026 | 41756179 | PubTator, text mining | PubMed |
| Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD. | Mol Ther Oncol | 2026 | 41716467 | PubTator, text mining | PubMed |
| Sex Differences in Response to Viral Vector Vaccines-Implications for Future Vaccine Design. | Immunol Rev | 2026 | 41612856 | PubTator, text mining | PubMed |
| Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. | Vaccines (Basel) | 2025 | 40266233 | PubTator, text mining | PubMed |
| Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. | Cancer Gene Ther | 2025 | 40057574 | PubTator, text mining | PubMed |
1 to 10 of 1,614
See all 1,614 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8081
GET https://conductscience.org/api/genes/v1/8081/grants?page=2